Predictive validity of animal pain models? A comparison of the pharmacokinetic–pharmacodynamic relationship for pain drugs in rats and humans

Anonymous, 2007

Beggs, 2006, Neuropathic pain: symptoms, models, and mechanisms, Drug Development Research, 67, 289, 10.1002/ddr.20094

Blackburn-Munro, 2005, Antiepileptics and the treatment of neuropathic pain: evidence from animal models, Current Pharmaceutical Design, 11, 2961, 10.2174/1381612054865000

Bresalier, 2005, The editor's roundtable: cyclooxygenase-2 inhibitors and cardiovascular risk, American Journal of Cardiology, 96, 1589, 10.1016/j.amjcard.2005.09.069

Campbell, 2006, Mechanisms of neuropathic pain, Neuron, 52, 77, 10.1016/j.neuron.2006.09.021

Castagne, 2006, Early behavioral screening for antidepressants and anxiolytics, Drug Development Research, 67, 729, 10.1002/ddr.20145

Castel-Branco, 2004, Lamotrigine kidney distribution in male rats following a single intraperitoneal dose, Fundamental & Clinical Pharmacology, 18, 51, 10.1046/j.0767-3981.2003.00210.x

Chan, 2007, Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects, British Journal of Clinical Pharmacology, 63, 310, 10.1111/j.1365-2125.2006.02770.x

Chen, 2002, Pharmacokinetic interactions between carbamazepine and the traditional Chinese medicine Paeoniae Radix, Biological & Pharmaceutical Bulletin, 25, 532, 10.1248/bpb.25.532

Colpaert, 2001, Opiate self-administration as a measure of chronic nociceptive pain in arthritic rats, Pain, 91, 33, 10.1016/S0304-3959(00)00413-9

Coulthard, 2003, Gait analysis as a correlate of pain induced by carrageenan intraplantar injection, Journal of Neuroscience Methods, 128, 95, 10.1016/S0165-0270(03)00154-7

Dickenson, 2002, Neurobiology of neuropathic pain: mode of action of anticonvulsants, European Journal of Pain London, 6, 51, 10.1053/eujp.2001.0323

Eaton, 2003, Common animal models for spasticity and pain, Journal of Rehabilitation Research and Development, 40, 41, 10.1682/JRRD.2003.08.0041

El Mouedden, 2007, Pharmacological evaluation of opioid and non-opioid analgesics in a murine bone cancer model of pain, Pharmacology Biochemistry and Behavior, 86, 458, 10.1016/j.pbb.2007.01.003

Fernihough, 2004, Pain related behaviour in two models of osteoarthritis in the rat knee, Pain, 112, 83, 10.1016/j.pain.2004.08.004

Fishbain, 2000, Evidence-based data from animal and human experimental studies on pain relief with antidepressants: a structured review, Pain Medicine, 1, 310, 10.1046/j.1526-4637.2000.00042.x

Fitzgerald, 2007, COX-2 in play at the AHA and the FDA, Trends in Pharmacological Sciences, 28, 303, 10.1016/j.tips.2007.05.007

Ghilardi, 2005, Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain, Journal of Neuroscience, 25, 3126, 10.1523/JNEUROSCI.3815-04.2005

Gidal, 1998, Gabapentin absorption: effect of mixing with foods of varying macronutrient composition, Annals of Pharmacotherapy, 32, 405, 10.1345/aph.17281

Guirguis, 2001, Phaumacokinetics of celecoxib in the presence and absence of interferon-induced acute inflammation in the rat: application of a novel HPLC assay, Journal of Pharmacy and Pharmaceutical Sciences, 4, 1

Hamilton, 2000, ATP in human skin elicits a dose-related pain response which is potentiated under conditions of hyperalgesia, Brain, 123, 1238, 10.1093/brain/123.6.1238

Hill, 2000, NK1 (substance P) receptor antagonists – why are they not analgesic in humans?, Trends in Pharmacological Sciences, 21, 244, 10.1016/S0165-6147(00)01502-9

Hill, 2004, Can the evaluation of drugs in animal pain models reliably predict the ability to produce clinical analgesia, 247

Honore, 2006, Behavioral assessment of neuropathic pain in preclinical models, Drug Development Research, 67, 302, 10.1002/ddr.20095

Hu, 2007, Immune cell involvement in dorsal root ganglia and spinal cord after chronic constriction or transection of the rat sciatic nerve, Brain Behavior and Immunity, 21, 599, 10.1016/j.bbi.2006.10.013

Iyengar, 2004, Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats, Journal of Pharmacology and Experimental Therapeutics, 311, 576, 10.1124/jpet.104.070656

Jarvis, 2002, A-317491, a novel potent and selective nonnucleotide antagonist of P2X(3) and P2X(2/3) receptors, reduces chronic inflammatory and neuropathic pain in the rat, Proceedings of the National Academy of Sciences of the United States of America, 99, 17179, 10.1073/pnas.252537299

Johansen, 2001, The affective component of pain in rodents: direct evidence for a contribution of the anterior cingulate cortex, Proceedings of the National Academy of Sciences of the United States of America, 98, 8077, 10.1073/pnas.141218998

Jose, 2007, Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy, Diabetic Medicine, 24, 377, 10.1111/j.1464-5491.2007.02093.x

Khosravan, 2006, Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs, Journal of Clinical Pharmacology, 46, 855, 10.1177/0091270006289848

Kim, 2000, Enhanced absorption of indomethacin after oral or rectal administration of a self-emulsifying system containing indomethacin to rats, International Journal of Pharmaceutics, 194, 81, 10.1016/S0378-5173(99)00367-1

Kontinen, 2003, Predictive validity of neuropathic pain models in pharmacological studies with a behvavioural outcome in the rat: a systematic review, 489

Lemberg, 2006, Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats, Anesthesiology, 105, 801, 10.1097/00000542-200610000-00027

Leventhal, 2007, Differential and synergistic effects of selective norepinephrine and serotonin reuptake inhibitors in rodent models of pain, Journal of Pharmacology and Experimental Therapeutics, 320, 1178, 10.1124/jpet.106.109728

Leykin, 2007, Highlights in postoperative pain treatment, Expert Review of Neurotherapeutics, 7, 533, 10.1586/14737175.7.5.533

Littlejohn, 2006, Fibromyalgia syndrome: which antidepressant drug should we choose, Current Pharmaceutical Design, 12, 3, 10.2174/138161206775193253

Matson, 2007, Inflammation-induced reduction of spontaneous activity by adjuvant: a novel model to study the effect of analgesics in rats, Journal of Pharmacology and Experimental Therapeutics, 320, 194, 10.1124/jpet.106.109736

McArthur, 2006, Animal models of depression in drug discovery: A historical perspective, Pharmacology Biochemistry and Behavior, 84, 436, 10.1016/j.pbb.2006.06.005

McWilliams, 2003, Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample, Pain, 106, 127, 10.1016/S0304-3959(03)00301-4

Moalem, 2006, Immune and inflammatory mechanisms in neuropathic pain, Brain Research Reviews, 51, 240, 10.1016/j.brainresrev.2005.11.004

Negus, 2006, Preclinical assessment of candidate analgesic drugs: recent advances and future challenges, Journal of Pharmacology and Experimental Therapeutics, 319, 507, 10.1124/jpet.106.106377

Pomonis, 2005, Development and pharmacological characterization of a rat model of osteoarthritis pain, Pain, 114, 339, 10.1016/j.pain.2004.11.008

Puozzo, 2006, Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipran, International Clinical Psychopharmacology, 21, 153, 10.1097/01.yic.0000188217.69537.dc

Radulovic, 1995, Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys, Drug Metabolism and Disposition, 23, 441

Rice, 2006, New treatments for neuropathic pain, Annual Review of Medicine, 57, 535, 10.1146/annurev.med.57.121304.131324

Rolke, 2006, Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values, Pain, 123, 231, 10.1016/j.pain.2006.01.041

Sams-Dodd, 1998, A test of the predictive validity of animal models of schizophrenia based on phencyclidine and d-amphetamine, Neuropsychopharmacology, 18, 293, 10.1016/S0893-133X(97)00161-9

Schwei, 1999, Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain, Journal of Neuroscience, 19, 10886, 10.1523/JNEUROSCI.19-24-10886.1999

Sullivan, 2007, Pharmacological characterization of the muscarinic agonist (3R,4R)-3-(3-hexylsulfanyl-pyrazin-2-yloxy)-1-aza-bicyclo[2.2.1]heptane (WAY-132983) in in vitro and in vivo models of chronic pain, Journal of Pharmacology and Experimental Therapeutics, 322, 1294, 10.1124/jpet.106.118604

Theis, 2005, Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine, Neuropsychopharmacology, 30, 2269, 10.1038/sj.npp.1300831

Urban, 2001, Chronic neuropathic pain: pathomechanism and pharmacology, Drug Development Research, 54, 159, 10.1002/ddr.10015

2006

Walker, 1999, Animal models for pain research, Molecular Medicine Today, 5, 319, 10.1016/S1357-4310(99)01493-8

Wang, 2002, Chronic neuropathic pain is accompanied by global changes in gene expression and shares pathobiology with neurodegenerative diseases, Neuroscience, 114, 529, 10.1016/S0306-4522(02)00341-X

Wantuch, 2007, Pharmacological validation of a model of cystitis pain in the mouse, Neuroscience Letters, 421, 250, 10.1016/j.neulet.2007.05.043

Whiteside, 2004, Pharmacological characterisation of a rat model of incisional pain, British Journal of Pharmacology, 141, 85, 10.1038/sj.bjp.0705568

Williams, 2006, Depression and pain: an overview, Acta Neuropsychiatrica, 18, 79, 10.1111/j.1601-5215.2006.00130.x